A woman at home using a conversational AI health assistant on her smartphone

    Ask Mima

    Validating a Conversational AI for Oncology Support

    Using Aria to combine longitudinal real-world use of a conversational health AI with in-depth patient research to inform digital health product development.

    • Conversational AI Validation
    • Digital Health
    • Oncology
    • Mixed-Methods Research
    • Ethics Approved

    Approved by the Cyprus National Bioethics Committee

    01

    The Challenge

    Digital health products designed for people living with cancer need to do more than function technically. They need to fit into patients’ everyday lives, respond to genuine needs and handle highly sensitive health information appropriately.

    Mima Health developed Ask Mima, a conversational AI platform designed to support people navigating oncology and chronic disease.

    The team wanted to understand both how patients interacted with the technology over time and the broader experiences, needs and challenges that should shape its future development.

    This required a research approach that could combine structured longitudinal data with deeper qualitative patient insight.

    02

    The Study

    Aria supported a two-part research programme evaluating the Ask Mima conversational AI and exploring the experiences of oncology patients.

    Real-World AI Use

    Participants used the Ask Mima technology twice daily for two weeks, while the study collected information about their interactions with the AI, anxiety levels and questionnaire responses.

    The technology was evaluated as a research tool rather than for diagnostic purposes, enabling the team to understand how people engaged with the platform during repeated real-world use.

    In-Depth Oncology Patient Research

    A separate qualitative research component involved 1–2 hour structured interviews with oncology patients.

    The interviews explored experiences from diagnosis through treatment and recovery, including interactions with healthcare providers, use of healthcare services and technology, access to support, the impact of cancer on daily life and opportunities to improve the patient experience.

    Together, the two research components provided both structured behavioural and patient-reported data and richer qualitative insight into the needs of people navigating cancer care.

    03

    Aria Enabled

    Longitudinal AI Interaction Tracking

    Participant use of the conversational AI was incorporated into a structured two-week study journey, enabling repeated real-world engagement with the technology to be evaluated.

    Questionnaires & Anxiety Tracking

    Aria captured structured questionnaire responses and anxiety measures alongside participants’ interactions with the AI.

    Mixed-Methods Research Delivery

    Quantitative longitudinal data and in-depth qualitative interviews were combined within one research programme, providing different perspectives on both the technology and the patient experience.

    Double-Pseudonymised Data Sharing

    Study data was securely managed through Aria, with Mima Health receiving double-pseudonymised data for analysis so that research data could not be linked back to individual participants.

    Digital Consent & Ethical Study Delivery

    Participants completed informed consent through My Aria before taking part, supporting ethically approved digital research involving sensitive oncology experiences and health information.

    04

    The Results

    The two-part programme generated complementary evidence around both the use of Ask Mima in practice and the wider needs and experiences of oncology patients.

    Longitudinal study data provided insight into engagement with the conversational AI alongside anxiety and questionnaire measures, while the qualitative interviews captured detailed patient perspectives on cancer care, technology use and areas where additional support or innovation may be valuable.

    Together, these findings provided Mima Health with structured evidence and patient insight to support the continued development of its technology.

    Ethically Approved Digital Health Research

    Both research components were conducted using participant consent materials approved by the Cyprus National Bioethics Committee, enabling sensitive oncology research to be delivered within a structured, privacy-conscious research framework.

    05

    Why It Matters

    Validating a digital health product requires more than asking users whether they liked it.

    Ask Mima demonstrated how Aria can combine real-world technology use, patient-reported measures and in-depth qualitative research to build a more complete picture of how a digital health product fits into patients’ lives.

    For digital health innovators, this approach can provide both the structured evidence needed to evaluate a product and the deeper patient insight needed to understand why users behave and respond the way they do.

    Validating a Digital Health Product?

    See how Aria can combine real-world product use, patient-reported data and qualitative research within one study.

    Build Your Study